Niclosamide (Standard)

Niclosamide (Standard) is the analytical standard of Niclosamide. This product is intended for research and analytical applications. Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells[2][3][5].

Product Specifications

CAS Number

[50-65-7]

Product Name Alternative

BAY2353 (Standard)

UNSPSC

12352005

Hazard Statement

H400, H410

Target

Antibiotic; Parasite; Reference Standards; STAT

Type

Reference Standards

Related Pathways

Anti-infection; JAK/STAT Signaling; Others; Stem Cell/Wnt

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/niclosamide-standard.html

Purity

99.16

Smiles

O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O

Molecular Formula

C13H8Cl2N2O4

Molecular Weight

327.12

Precautions

H400, H410

References & Citations

[1]P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19 (2) :245-95.|[2]Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96.|[3]Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22 (14) :3458-66.|[4]Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1 (9) :454-9.|[5]Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48 (7) :2693-6.